A Study Investigating the Pharmacokinetic Properties When Dosing Different Formulations of Semaglutide to Healthy Male Participants - Oral Formulation III
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Alzheimer's disease; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 30 Apr 2024 Status changed from recruiting to completed.
- 26 Oct 2023 New trial record